Amgen Inc. SEC filings document the regulatory record for a Nasdaq-listed biotechnology company with common stock and registered debt securities. Its 8-K reports cover quarterly and annual earnings releases, Regulation G reconciliations for non-GAAP measures, free cash flow disclosures, material definitive agreements, executive leadership changes and capital markets transactions.
The company's proxy materials describe annual meeting matters, board governance, executive compensation and stockholder voting procedures. Other filings address senior note offerings under registration statements and indentures, Nasdaq listing and registration matters for debt securities, and formal exhibits that define the terms of financing, governance and corporate disclosure events.
Amgen Inc. EVP & CFO Peter H. Griffith reported two tax-related share dispositions of company common stock. On May 2, 2026, he delivered 687 shares and 746 shares of Amgen stock at $329.82 per share each as tax-withholding transactions, not open-market sales.
After these dispositions, his reported direct holdings in Amgen common stock were 47,568 shares following one transaction and 48,255 shares following the other. A footnote notes that his holdings include 454 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares as the awards vest.
Amgen Inc. executive vice president and general counsel Jonathan P. Graham reported two routine tax-related share dispositions. On May 2, 2026, a total of 1,257 shares of Amgen common stock were withheld at $329.82 per share to satisfy tax obligations on equity awards, rather than sold on the open market. Following these transactions, his reported direct holdings in the affected accounts were 38,010 and 38,620 shares of common stock.
Amgen Inc. executive Gordon Murdo reported routine tax-related share dispositions, not open-market sales. On May 2, 2026, he had 1,593 shares of common stock withheld at $329.82 per share to cover tax obligations. Following these transactions, he directly holds 48,699 Amgen shares.
A footnote explains his holdings include 488 Dividend Equivalents tied to unvested Restricted Stock Units under Amgen’s equity incentive plan, which pay out in shares according to the vesting schedule.
Amgen Inc. vice president, finance and chief accounting officer Matthew C. Busch reported routine share dispositions related to tax withholding. On May 2, 2026, a total of 68 shares of common stock were withheld at $329.82 per share to satisfy tax obligations tied to equity awards.
Following these transactions, Busch directly holds 3,980 shares of Amgen common stock. A footnote explains that his holdings include 49 Dividend Equivalents linked to unvested Restricted Stock Units, which will be settled in common shares as those units vest.
AMGEN INC Chairman, CEO and President Robert A. Bradway reported routine equity-related activity in company stock. The filing shows tax-withholding dispositions totaling 5,057 shares of common stock at $329.82 per share, used to cover exercise price or tax liabilities tied to equity awards.
Bradway also reports indirect holdings in Amgen common stock through his spouse and related GRATs, alongside Dividend Equivalents credited to unvested Restricted Stock Units that pay out in shares as they vest. These transactions do not reflect open-market buying or selling decisions.
Amgen Inc. reported higher quarterly results for the three months ended March 31, 2026. Total revenues rose to $8.6 billion from $8.1 billion a year earlier, driven by product sales of $8.2 billion, notably from Repatha, Prolia, EVENITY, TEPEZZA and other key therapies.
Net income increased to $1.8 billion from $1.7 billion, with diluted EPS of $3.34 versus $3.20. Operating income more than doubled to $2.7 billion, helped by lower cost of sales and the absence of prior-year intangible impairments, partly offset by higher R&D spending.
Cash from operating activities rose to $2.2 billion, and cash and cash equivalents reached $12.0 billion, while total assets were $92.5 billion and total debt $58.8 billion. The company continues to face tax disputes with the IRS that could be material and highlighted regulatory scrutiny of TAVNEOS and pricing pressures from U.S. policy changes, including the Inflation Reduction Act.
Amgen Inc. reported solid first quarter 2026 results, with total revenues rising 6% to $8.6 billion, supported by 4% product sales growth driven by 9% higher volumes. Sixteen products delivered double-digit sales growth and seventeen are tracking at more than $1 billion in annualized sales.
GAAP earnings per share increased from $3.20 to $3.34, while non-GAAP EPS grew from $4.90 to $5.15. GAAP operating income rose from $1.2 billion to $2.7 billion, expanding GAAP operating margin to 32.4%, though non-GAAP operating margin edged down to 45.3%.
The company generated $1.5 billion of free cash flow versus $1.0 billion a year earlier and paid a quarterly dividend of $2.52 per share, up 6%. Management reaffirmed the use of extensive non-GAAP measures and guided 2026 non-GAAP diluted EPS to a range of $21.70–$23.10, compared with GAAP EPS guidance of $15.62–$17.10.
Amgen Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 40,510,484 shares of Amgen common stock, representing 7.51% of the class as of 03/31/2026. The filing shows 5,496,252 shares with sole voting power and 40,510,484 shares with sole dispositive power.
Amgen Inc. announced that David M. Reese, M.D., executive vice president and Chief Technology Officer, will retire from his executive roles effective June 30, 2026. He will remain an executive vice president until that date and receive retirement benefits under existing company plans.
To support Amgen’s focus on combining biology, data science and advanced technologies, the company is redistributing Reese’s responsibilities effective June 1, 2026. James Bradner, M.D., will serve as executive vice president, Research and Development, Artificial Intelligence and Data; Sean Bruich will become senior vice president and Chief Technology Officer; and Murdo Gordon will lead Amgen Global Markets and Policy as executive vice president. These changes are intended to deepen the integration of science and technology across research, medical, commercial and policy functions.